TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38421092

Group type: COMPARATOR
Intervention: Seated resting-state heart rate variability (HRV) parameters in the α-OH group
Number of subjects: 81

Group type: COMPARATOR
Intervention: Seated resting-state HRV parameters in the α-NOH group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Correlation of HRV parameters with blood pressure changes
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Seated resting-state qEEG parameters in the α-OH group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Peak frequency of theta waves in the Cz region
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Power of beta2 waves in Fp2 and F4 regions
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Abnormal electrical activity in alpha, theta, and beta1 waves
Number of subjects: 81
Study: 38421211

Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y reconstruction
Number of subjects: 1167
Study: 38421404

Group type: EXPERIMENTAL
Intervention: Venetoclax monotherapy
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Venetoclax in combination with rituximab
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Venetoclax in combination with obinutuzumab
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Specific treatment for TLS
Number of subjects: 239
Study: 38421421

Group type: EXPERIMENTAL
Intervention: LNG-IUS-19.5 mg
Number of subjects: 508
Study: 38421647

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Metformin plus lifestyle intervention
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Metformin plus rosiglitazone
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Increase in IGF-1 level
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Increase in GHR level
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Increase in IGFBP-1 level
Number of subjects: 398
Study: 38421648

Group type: EXPERIMENTAL
Intervention: Interpersonal behavior change strategies (BCSs) combined with the Otago Exercise Program
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Intrapersonal behavior change strategies (BCSs) combined with the Otago Exercise Program
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Intrapersonal and interpersonal BCSs combined with the Otago Exercise Program
Number of subjects: 309

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 309
Study: 38421649

Group type: EXPERIMENTAL
Intervention: Video telemedicine consultations
Number of subjects: 696

Group type: COMPARATOR
Intervention: Telephone consultations
Number of subjects: 696
Study: 38421662

Group type: EXPERIMENTAL
Intervention: Cone or cone-rod dystrophy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cone-rod dystrophy
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Outer nuclear layer thickness
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ataxia severity
Number of subjects: 15
Study: 38421679

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Glucocorticoid injection
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injection
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: PRP injection
Number of subjects: 120
Study: 38421757

Group type: EXPERIMENTAL
Intervention: Internet-based acceptance and commitment therapy (iACT)
Number of subjects: 0
Study: 38421881

Group type: EXPERIMENTAL
Intervention: Ensartinib 225 mg orally once daily
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: High ctDNA levels evaluated by variant allele frequency (VAF) and haploid genome equivalents per milliliter of plasma (hGE/mL) at baseline
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: ctDNA clearance at 6 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lower tumor burden evaluated by the diameter of target lesions
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Baseline ALK or TP53 mutation
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Multivariate Cox regression analysis
Number of subjects: 180
Study: 38421922

Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 2 mg
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: ADT + brexpiprazole 2-3 mg
Number of subjects: 746

Group type: COMPARATOR
Intervention: ADT + placebo
Number of subjects: 746
Study: 38421921

Group type: EXPERIMENTAL
Intervention: Valbenazine 40 mg
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Valbenazine 80 mg
Number of subjects: 256

Group type: COMPARATOR
Intervention: Valbenazine (both doses)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Clinical Global Impression of TD scores
Number of subjects: 256

Group type: COMPARATOR
Intervention: Treatment-emergent adverse events
Number of subjects: 256
Study: 38422316

Group type: EXPERIMENTAL
Intervention: Classical foot massage
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (no applications)
Number of subjects: 71
Study: 38422320

Group type: EXPERIMENTAL
Intervention: Upper limb position sustained isometric task
Number of subjects: 31
Study: 38422375

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (education about SDB and PAP, goal setting, troubleshooting, motivational enhancement)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control (non-directive sleep education)
Number of subjects: 63
Study: 38422450

Group type: EXPERIMENTAL
Intervention: User-centred habit-formation intervention
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study: 38422473

Group type: EXPERIMENTAL
Intervention: Experimental treatment (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (specifics not provided)
Number of subjects: 0
Study: 38422496

Group type: EXPERIMENTAL
Intervention: Antibiotics (25 mg/kg cefazolin IV up to 1g or clindamycin 10 mg/kg up to 600 mg IV in case of cefazolin allergy)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (10-mL prefilled syringe of normal saline)
Number of subjects: 160
Study: 38422505

Group type: EXPERIMENTAL
Intervention: Tension group (n=138)
Number of subjects: 279

Group type: COMPARATOR
Intervention: No-tension group (n=141)
Number of subjects: 279
Study: 38422585

Group type: EXPERIMENTAL
Intervention: CBP501 16 mg/m, cisplatin, nivolumab
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CBP501 25 mg/m, cisplatin, nivolumab
Number of subjects: 36

Group type: COMPARATOR
Intervention: cisplatin, nivolumab
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CBP501 (unknown dosage), cisplatin, nivolumab
Number of subjects: 36
Study: 38422781

Group type: EXPERIMENTAL
Intervention: ROTEM's EXTEM-CFT
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ROTEM's FIBTEM-MCF
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: D-dimer
Number of subjects: 60

Group type: COMPARATOR
Intervention: ROTEM parameters and D-dimer
Number of subjects: 60
Study: 38422947

Group type: EXPERIMENTAL
Intervention: DEAR weight management
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 38422953

Group type: EXPERIMENTAL
Intervention: Low-inflammatory Mediterranean dietary intervention
Number of subjects: 27
Study: 38423010

Group type: EXPERIMENTAL
Intervention: Bi-allelic SNF8 variants
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mildly affected individuals with hypomorphic variant c.304G>A (p.Val102Ile)
Number of subjects: 9
Study: 38423021

Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccination (0.1 mL intradermal injection)
Number of subjects: 1985

Group type: COMPARATOR
Intervention: Placebo (intradermal injection of 0.9% saline)
Number of subjects: 1985

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 1985

Group type: EXPERIMENTAL
Intervention: BCG-Denmark vaccination
Number of subjects: 1985
Study: 38423024

Group type: EXPERIMENTAL
Intervention: 3×3 screening for N gonorrhoeae and C trachomatis
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Non-screening for N gonorrhoeae and C trachomatis
Number of subjects: 1014
Study: 38423030

Group type: EXPERIMENTAL
Intervention: GRPR-targeting radiopharmaceutical
Number of subjects: 100
Study: 38423047

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) - 23 patients received single-fraction SABR of 26 Gy, 47 patients received 42 Gy in three fractions.
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR)
Number of subjects: 70
Study: 38423051

Group type: EXPERIMENTAL
Intervention: Pivekimab sunirine at 0.045 mg/kg once every 3 weeks (recommended phase 2 dose)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pivekimab sunirine at doses of 0.015 mg/kg to 0.450 mg/kg (schedule A)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Pivekimab sunirine (schedule A)
Number of subjects: 91
Study: 38423215

Group type: EXPERIMENTAL
Intervention: Low-dose cotoretigene toliparvovec (5 × 10^11 vg/mL)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-dose cotoretigene toliparvovec (5 × 10^12 vg/mL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low-dose cotoretigene toliparvovec
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High-dose cotoretigene toliparvovec
Number of subjects: 29
Study: 38423547

Group type: EXPERIMENTAL
Intervention: Sunflower seed oil (SSO)
Number of subjects: 32114

Group type: COMPARATOR
Intervention: Mustard oil (MO)
Number of subjects: 32114
Study: 38423549

Group type: EXPERIMENTAL
Intervention: Data-Informed Platform for Health intervention
Number of subjects: 24
Study: 38423582

Group type: EXPERIMENTAL
Intervention: Mindfulness-based programmes (MBPs)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Light physical exercise (LE)
Number of subjects: 241
Study: 38423700

Group type: EXPERIMENTAL
Intervention: idecabtagene vicleucel (ide-cel)
Number of subjects: 386

Group type: COMPARATOR
Intervention: standard regimens (daratumumab, pomalidomide, and dexamethasone; daratumumab, bortezomib, and dexamethasone; ixazomib, lenalidomide, and dexamethasone; carfilzomib and dexamethasone; or elotuzumab, pomalidomide, and dexamethasone)
Number of subjects: 386
Study: 38423752

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) protocol
Number of subjects: 2397

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 2397
Study: 38423758

Group type: EXPERIMENTAL
Intervention: Intervention: Not specified (observational study)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Intervention: TNF inhibitors (TNFi) as a time-varying covariate
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Baseline bone marrow oedema (BME) on MRI of the sacroiliac joints (SIJ)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Male sex, symptom duration >1.5 years, Axial Spondyloarthritis Disease Activity Score ≥2.1, smoking (only in HLA-B27 positives)
Number of subjects: 659

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 659
Study: 38423765

Group type: EXPERIMENTAL
Intervention: Intravenous thiamine (200 mg in 50 mL 0.9% saline)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (0.9% saline identical in appearance and volume)
Number of subjects: 100
Study: 38423770

Group type: EXPERIMENTAL
Intervention: Intensive glycaemic targets (fasting <90 mg/dL and 1-hour postprandial <120 mg/dL)
Number of subjects: 828

Group type: COMPARATOR
Intervention: Standard glycaemic targets (fasting <95 mg/dL and 1-hour postprandial <140 mg/dL)
Number of subjects: 828
Study: 38423771

Group type: EXPERIMENTAL
Intervention: Multidomain adaptive cognitive training (CCT) for 12 weeks, 30 min/day, 5 days/week
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-adaptive cognitive training (active control) for 12 weeks, 30 min/day, 5 days/week
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Multidomain adaptive cognitive training (CCT)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-adaptive cognitive training (active control)
Number of subjects: 200
Study: 38423778

Group type: EXPERIMENTAL
Intervention: Mobilisation within 6 hours postoperatively
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: Mobilisation within 12 hours postoperatively
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: Mobilisation within 24 hours postoperatively
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: Standing up by the bed
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: Walking away from the bedside
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: Factors associated with mobilisation within 6 hours
Number of subjects: 1492

Group type: EXPERIMENTAL
Intervention: Time to mobilisation after major upper abdominal surgery
Number of subjects: 1492
Study: 38423814

Group type: EXPERIMENTAL
Intervention: Co-administration of RZV with other vaccines
Number of subjects: 3974

Group type: EXPERIMENTAL
Intervention: Co-administration of RZV with PPSV23
Number of subjects: 3974
Study: 38423866

Group type: EXPERIMENTAL
Intervention: Niraparib 1 × 300-mg tablet
Number of subjects: 150

Group type: COMPARATOR
Intervention: 3 × 100-mg capsules
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Niraparib 1 × 300-mg tablet in fed state (high-fat meal)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Niraparib 1 × 300-mg tablet in fasted state
Number of subjects: 150
Study: 38423992

Group type: EXPERIMENTAL
Intervention: Avacopan 30 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avacopan 30 or 60 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avacopan co-administered with itraconazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avacopan co-administered with rifampin
Number of subjects: 0
Study: 38424099

Group type: EXPERIMENTAL
Intervention: Prebiotic
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 38424224

Group type: EXPERIMENTAL
Intervention: Rectangular braided steel retention wire (0.673 × 0.268 mm) bonded to the lingual surfaces of all mandibular teeth from canine to canine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Round twisted steel wire (0.406 mm)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group with vacuum-formed retainers only (no wires)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: All groups had vacuum-formed removable retainers in the maxilla
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Rectangular wire
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Round wire
Number of subjects: 66
Study: 38424308

Group type: EXPERIMENTAL
Intervention: Encorafenib (450 mg QD) and binimetinib (45 mg BID)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosuvastatin (10 mg) and Bupropion (75 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Encorafenib (300 mg QD) and cetuximab (400 mg/m2)
Number of subjects: 0
Study: 38424319

Group type: EXPERIMENTAL
Intervention: Bone resorption markers (C-telopeptide (CTx), Pyridinoline (PYD)) and bone formation markers (C-terminal collagen propeptide (CICP), bone alkaline phosphatase (BAP)) assessed in blood.
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Bone biomarkers (CICP, CTX, PYD)
Number of subjects: 713
Study: 38424344

Group type: EXPERIMENTAL
Intervention: EBQI (Evidence-Based Quality Improvement)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no EBQI)
Number of subjects: 12
Study: 38424537

Group type: EXPERIMENTAL
Intervention: Vortioxetine (5-20 mg, n=73)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (n=74)
Number of subjects: 200
Study: 38424609

Group type: EXPERIMENTAL
Intervention: Integrated exercise intervention (16-week group-based, workouts twice a week, endurance and resistance training)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 324
Study: 38424616

Group type: EXPERIMENTAL
Intervention: Iontophoresis of acetylcholine (ACh)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Iontophoresis of sodium nitroprusside (SNP)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preoperative peak amplitude at iontophoresis of ACh
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: AKI occurrence
Number of subjects: 60
Study: 38424744

Group type: EXPERIMENTAL
Intervention: Nonmedically attended RSV episodes
Number of subjects: 993

Group type: COMPARATOR
Intervention: Medically attended RSV
Number of subjects: 993
Study: 38425141

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG-IUS)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Oral megestrol acetate (MA) 160 mg
Number of subjects: 148
Study: 38425284

Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole 0.5-2 mg/day
Number of subjects: 120
Study: 38425446

Group type: EXPERIMENTAL
Intervention: Tofacitinib (oral Janus kinase inhibitor)
Number of subjects: 1156
Study: 38425462

Group type: EXPERIMENTAL
Intervention: Recovery coaching training curriculum (150 hours of training)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Recovery coaching services sustained by 72% of agencies after study period
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Training program completion
Number of subjects: 93
Study: 38425473

Group type: EXPERIMENTAL
Intervention: ECG247 Smart Heart Sensor system
Number of subjects: 40
Study: 38425504

Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC5) administered intravenously every 21 days for 6-9 cycles
Number of subjects: 16
Study: 38425785

Group type: EXPERIMENTAL
Intervention: High-frequency multimodal training
Number of subjects: 28
Study: 38425987

Group type: EXPERIMENTAL
Intervention: Irinotecan (180 mg/m2) administered in 28-day cycles
Number of subjects: 98
Study: 38426292

Group type: EXPERIMENTAL
Intervention: Melflufen and dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38426484

Group type: EXPERIMENTAL
Intervention: Walking fatigability (WF) assessed using the distance walk index (DWI)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Cognitive fatigability (CF) assessed using the SDMT
Number of subjects: 298

Group type: COMPARATOR
Intervention: Clinical characteristics comparison between WF and non-WF groups
Number of subjects: 298

Group type: COMPARATOR
Intervention: Comparison of CF and non-CF groups
Number of subjects: 298
Study: 38426479

Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccination
Number of subjects: 5000000

Group type: COMPARATOR
Intervention: No vaccination
Number of subjects: 5000000
Study: 38426741

Group type: EXPERIMENTAL
Intervention: Wide band of keratinized mucosa (WKM ≥ 2 mm)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Narrow/no band of keratinized mucosa (NKM < 2 mm)
Number of subjects: 38
Study: 38426763

Group type: EXPERIMENTAL
Intervention: Subclinical atherosclerosis (SA) burden (measured by coronary artery calcification scoring (CACS) and peripheral SA burden)
Number of subjects: 712
Study: 38426909

Group type: EXPERIMENTAL
Intervention: Fully Closed-Loop Insulin Delivery
Number of subjects: 0
Study: 38427038

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri NCIMB 30351 drops (5 drops, 2 times a day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 38427039

Group type: EXPERIMENTAL
Intervention: Exclusion of routine gastric residual measurement
Number of subjects: 88

Group type: COMPARATOR
Intervention: Routine gastric residual measurement
Number of subjects: 88
Study: 38427076

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion during a hyperinsulinaemic-euglycaemic clamp in participants with type 1 diabetes
Number of subjects: 27

Group type: COMPARATOR
Intervention: Adrenaline infusion during a hyperinsulinaemic-euglycaemic clamp in healthy participants
Number of subjects: 27
Study: 38427220

Group type: EXPERIMENTAL
Intervention: Omidubicel-onlv (20% use)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Omidubicel-onlv
Number of subjects: 10000
Study: 38427269

Group type: EXPERIMENTAL
Intervention: Cooperative Learning (CL) with technology support
Number of subjects: 813
Study: 38427322

Group type: EXPERIMENTAL
Intervention: Combination A (flexible single-channel EEG headband + actigraphy)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Flexible headband alone
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination B (rigid single-channel EEG headband + actigraphy)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Rigid headband alone
Number of subjects: 23
Study: 38427366

Group type: EXPERIMENTAL
Intervention: Roux-en-y gastric bypass (RYGB)
Number of subjects: 123
Study: 38427368

Group type: EXPERIMENTAL
Intervention: Trunk-oriented exercises
Number of subjects: 30

Group type: COMPARATOR
Intervention: Whole-body vibration
Number of subjects: 30
Study: 38427387

Group type: EXPERIMENTAL
Intervention: Higher PA instability (within-person)
Number of subjects: 24
Study: 38427485

Group type: EXPERIMENTAL
Intervention: Pimavanserin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38427753

Group type: EXPERIMENTAL
Intervention: ctDNA mutations of KRAS, TP53, DIS3, BRAF, NRAS, and ATM
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: BMPC mutations of TP53 and KRAS
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: KRAS mutations detected in both BMPC and ctDNA
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Total number of ctDNA mutations in 6 relevant genes
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Prognostic index using ctDNA mutations, plasma DNA concentration, and clinical factors
Number of subjects: 261
Study: 38427923

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38427930

Group type: EXPERIMENTAL
Intervention: Laboratory-developed test (LDT) for HRD
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Functional RAD51 assay
Number of subjects: 91

Group type: COMPARATOR
Intervention: CDx HRD testing
Number of subjects: 91
Study: 38428259

Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg oral dose
Number of subjects: 20
Study: 38428265

Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (Pemetrexed Cisplatin)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Personalized treatment based on EGFR mutation (Erlotinib) and ERCC1 expression
Number of subjects: 134

Group type: COMPARATOR
Intervention: KRAS mutations
Number of subjects: 134

Group type: COMPARATOR
Intervention: Isolated STK11/LKB1 mutations
Number of subjects: 134
Study: 38428428

Group type: EXPERIMENTAL
Intervention: Idebenone treatment (900 mg/day) for 24 months
Number of subjects: 199

Group type: COMPARATOR
Intervention: Natural history control cohort
Number of subjects: 199